CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.21B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.21BUSDvs all stocks (USD)
Revenue (TTM)
105.00MUSDvs all stocks (USD)
Profit Margin
-285.33%vs Biotechnology peers
Beta
1.97xvs all stocks
52-Week Change
91.37%vs all stocks
Market Capitalization
9.21BUSDvs all stocks (USD)
Enterprise Value
8.70BUSDvs all stocks (USD)
Forward P/E
-21.95xvs Biotechnology peers
Price to Sales (TTM)
87.70xvs Biotechnology peers
Price to Book (MRQ)
6.14xvs Biotechnology peers
Enterprise to Revenue
82.82xvs Biotechnology peers
Enterprise to EBITDA
-25.59xvs Biotechnology peers
Profit Margin
-285.33%vs Biotechnology peers
Operating Margin
-116.32%vs Biotechnology peers
Return on Assets (TTM)
-15.59%vs Biotechnology peers
Return on Equity (TTM)
-24.15%vs Biotechnology peers
Revenue (TTM)
105.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.13USDUpdated Sep 27, 2026Quarterly Revenue Growth
466.40%vs Biotechnology peers
Gross Profit (TTM)
-270.57MUSDvs all stocks (USD)
EBITDA (TTM)
-339.89MUSDvs all stocks (USD)
Net Income (TTM)
-299.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
466.40%vs Biotechnology peers
Operating Cash Flow (TTM)
-236.76MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-144.07MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
39.21MUSDFY2025 · Dec 31, 2025Operating Income
-345.54MUSDvs all stocks (USD)
Pre-tax Income
-311.35MUSDFY2025 · Dec 31, 2025Net Income
-311.35MUSDFY2025 · Dec 31, 2025EBIT
-310.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-298.81MUSDFY2025 · Dec 31, 2025Research & Development
316.57MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
68.19MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
38.42MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
370.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-311.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-232.89MUSDFY2025 · Dec 31, 2025Free Cash Flow
-234.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
362.81MUSDFY2025 · Dec 31, 2025Interest Paid
312.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-311.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
8.31MUSDFY2025 · Dec 31, 2025Stock-based Compensation
59.90MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
947.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.97MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.27MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.45MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.01BUSDFY2025 · Dec 31, 2025Sale of Investments
488.02MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-521.06MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.49MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
927.41MUSDFY2025 · Dec 31, 2025Shares Outstanding
82.79MSharesUpdated Sep 27, 2026Float Shares
66.01MSharesUpdated Sep 27, 2026Shares Short
10.53MSharesUpdated Sep 27, 2026Short Ratio
16.35daysvs all stocks
Short % of Shares Outstanding
16.29%vs all stocks
% Held by Insiders
2.12%vs all stocks
% Held by Institutions
119.27%vs all stocks
Total Cash (MRQ)
690.99MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.31USDUpdated Sep 27, 2026Total Debt (MRQ)
78.56MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0520xvs Biotechnology peers
Current Ratio (MRQ)
10.34xvs Biotechnology peers
Book Value per Share (MRQ)
18.23USDUpdated Sep 27, 2026Total Assets
1.74BUSDvs all stocks (USD)
Total Current Assets
871.21MUSDFY2025 · Dec 31, 2025Total Liabilities
163.15MUSDFY2025 · Dec 31, 2025Total Non-current Assets
871.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
79.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
83.21MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
357.01MUSDFY2025 · Dec 31, 2025Other Short-term Investments
491.26MUSDFY2025 · Dec 31, 2025Accounts Payable
4.01MUSDFY2025 · Dec 31, 2025Short-term Debt
13.76MUSDFY2025 · Dec 31, 2025Deferred Revenue
22.93MUSDFY2025 · Dec 31, 2025Other Current Liabilities
242.00KUSDFY2025 · Dec 31, 2025Long-term Debt
68.50MUSDFY2025 · Dec 31, 2025Common Stock (Book)
8.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.07BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.58BUSDvs all stocks (USD)
52-Week Low
54.09USDUpdated Sep 27, 202652-Week High
130.05USDUpdated Sep 27, 202652-Week Change
91.37%vs all stocks
Beta
1.97xvs all stocks
50-Day MA
114.70USDUpdated Sep 27, 2026200-Day MA
92.38USDUpdated Sep 27, 2026Avg 10-Day Volume
845.05KSharesUpdated Sep 27, 2026Avg 30-Day Volume
701.58KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-3.25USDUpdated Sep 27, 2026Other Income / Expense
-3.85MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.21B, above the global median of $1.15BNotable
Market cap (USD): 9,208,736,976Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule